North America’s pharma industry saw a drop of 4.8% in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 80 pharma industry deals worth $4.53bn were announced for the region in March 2019, against the 12-month average of 84 deals.
Of all the deal types, venture financing saw most activity in March 2019 with 61 transactions, representing a 76.3% share for the region.
In second place was M&A with 17 deals, followed by private equity deals with two transactions, respectively capturing a 21.3% and 2.5% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s pharma industry with $3.53bn, while venture financing and private equity deals totalled $833.44m and $171.2m, respectively.
North America pharma industry deals in March 2019: Top deals
The top five pharma deals accounted for 79.7% of the overall value during March 2019.
The combined value of the top five pharma deals stood at $3.61bn, against the overall value of $4.53bn recorded for the month. The top announced pharma deal tracked by GlobalData in March 2019 was Thermo Fisher Scientific ‘s $1.7bn acquisition of Brammer Bio.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.